CoreFirst Bank & Trust’s AstraZeneca AZN Stock Holding History

CoreFirst Bank & Trust’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20	Closed	-$3.68K	–	291
2025 Q4	$3.68K	Sell	20 -100	-83%	-$17.5K	﹤0.01%	294
2025 Q3	$18.4K	Hold	120	–	–	0.01%	264
2025 Q2	$16.8K	Buy	+120	New	+$16.8K	0.01%	276
2025 Q1	–	Sell	-120	Closed	-$15.7K	–	129
2024 Q4	$15.7K	Hold	120	–	–	0.01%	280
2024 Q3	$18.7K	Buy	+120	New	+$19.4K	0.01%	268
2024 Q2	–	Sell	-120	Closed	-$16.3K	–	140
2024 Q1	$16.3K	Hold	120	–	–	0.01%	283
2023 Q4	$16.2K	Hold	120	–	–	0.01%	289
2023 Q3	$16.3K	Buy	120 +20	+20%	+$2.73K	0.01%	301
2023 Q2	$14.3K	Buy	+100	New	+$14.7K	0.01%	298
2022 Q1	–	Sell	-700	Closed	-$81K	–	391
2021 Q4	$81K	Hold	700	–	–	0.05%	204
2021 Q3	$84K	Hold	700	–	–	0.06%	198
2021 Q2	$84K	Hold	700	–	–	0.06%	199
2021 Q1	$70K	Hold	700	–	–	0.05%	208
2020 Q4	$70K	Buy	+700	New	+$74.1K	0.05%	190

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

CoreFirst Bank & Trust's AZN Position: Q1 2026 in Review

CoreFirst Bank & Trust sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 20 shares — an estimated $3.68K sold.

CoreFirst Bank & Trust first reported a position in AZN in Q4 2020 and held it in 14 quarters. The position peaked at $84K in Q3 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

CoreFirst Bank & Trust reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
CoreFirst Bank & Trust sold 20 AstraZeneca shares in Q1 2026, an estimated $3.68K.
CoreFirst Bank & Trust first reported a position in AstraZeneca in Q4 2020 and held it in 14 quarters.
CoreFirst Bank & Trust's AstraZeneca position peaked at $84K in Q3 2021.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on CoreFirst Bank & Trust's 13F filing for Q1 2026, filed 3 Jun 2026.